The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Cancer incidence and mortality in China, 2022
Open accessAbstract
Background: The National Cancer Center (NCC) of China regularly reports the nationwide statistics on cancer incidence and mortality in China. The International Agency for Research on Cancer (IARC) calculates and publishes the cancer burden of countries around the world every two years. To ensure consistency between the actual surveillance data in China and the data published by IARC, NCC has received approval from the National Health Commission and IARC to simultaneously release the cancer burden data for China in GLOBOCAN 2022. Methods: There were a total of 700 registries reporting high-quality data on cancer incidence and mortality across China in 2018, of which 106 registries with continuous monitoring from 2010 to 2018 were used to establish an age-period-cohort model to simulate the trend of cancer incidence and mortality and to estimate the incidence and mortality in China in 2022. In addition, we analyzed the temporal trends of age-standardized cancer incidence and mortality from 2000 to 2018 using data from 22 continuous cancer registries. Results: It was estimated about 4,824,700 new cancer cases and 2,574,200 new cancer deaths occurred in China in 2022. Cancers of the lung, colon-rectum, thyroid, liver and stomach were the top five cancer types, accounting for 57.42% of new cancer cases. Cancers of the lung, liver, stomach, colon-rectum and esophagus were the five leading causes of cancer deaths, accounting for 67.50% of total cancer deaths. The crude rate and age-standardized incidence rate (ASIR) were 341.75 per 100,000 and 201.61 per 100,000, respectively. The crude mortality rate was 182.34 per 100,000 and the age-standardized mortality rate (ASMR) was 96.47 per 100,000. The ASIR of all cancers combined increased by approximately 1.4% per year during 2000-2018, while the ASMR decreased by approximately 1.3% per year. We observed decreasing trends in ASIR and ASMR for cancers of the esophagus, stomach, and liver, whereas the ASIR increased significantly for cancers of the thyroid, prostate, and cervix. Conclusions: Cancer remains a major public health concern in China, with a cancer profile that reflects the coexistence of developed and developing regions. Sustained implementation of prevention and control measures has resulted in significant reductions in the incidence and mortality rates of certain historically high incidence cancers, such as esophageal, stomach and liver cancers. Adherence to the guidelines of the Healthy China Action Plan and the Cancer Prevention and Control Action Plan, along with continued efforts in comprehensive risk factor control, cancer screening, early diagnosis and treatment, and standardization of diagnostic and therapeutic protocols, are key strategies to effectively mitigate the increasing cancer burden by 2030.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689
Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70211-5 · Cited by 2,223
Cancer incidence and mortality in China, 2016
Zheng, R., Zhang, S., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.02.002 · Cited by 1,494
Self-citationBray, F., & Parkin, D. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.032 · Cited by 628
Evaluation of data quality in the cancer registry: Principles and methods Part II. Completeness
Parkin, D. M., & Bray, F. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.033 · Cited by 536
Cancer registration in China and its role in cancer prevention and control
Wei, W., Zeng, H., Zheng, R., Zhang, S., An, L., Chen, R., Wang, S., Sun, K., Matsuda, T., Bray, F., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30073-5 · Cited by 497
Self-citationCancer incidence and mortality in China, 2015
Zhang, S., Sun, K., Zheng, R., Zeng, H., Wang, S., Chen, R., Wei, W., & He, J. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2020.12.001 · Cited by 389
Self-citationPrevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
Cui, F., Shen, L., Li, L., Wang, H., Wang, F., Bi, S., Liu, J., Zhang, G., Wang, F., Zheng, H., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2305.161477 · Cited by 362
Self-citationLiver cancer incidence and mortality in China: Temporal trends and projections to 2030
Zheng, R., Office for Cancer Registry, N. C. C. C. R. C. F. C. H., Qu, C., Zhang, S., Zeng, H., Sun, K., Gu, X., Xia, C., Yang, Z., Li, H., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.06.01 · Cited by 343
Self-citationWei, W.-Q., Chen, Z.-F., He, Y.-T., Feng, H., Hou, J., Lin, D.-M., Li, X.-Q., Guo, C.-L., Li, S.-S., Wang, G.-Q., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0423 · Cited by 329
Self-citationChen, R., Liu, Y., Song, G., Li, B., Zhao, D., Hua, Z., Wang, X., Li, J., Hao, C., Zhang, L., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-320200 · Cited by 222
Self-citationCervical cancer prevention in China: a key to cancer control
Zhao, F., & Qiao, Y. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32849-6 · Cited by 152
Provincial-level cancer burden attributable to active and second-hand smoking in China
Xia, C., Zheng, R., Zeng, H., Zhou, M., Wang, L., Zhang, S., Zou, X., Sun, K., Yang, Z., Li, H., et al. (2018) · Tobacco Control · doi:10.1136/tobaccocontrol-2018-054583 · Cited by 58
Self-citationCui, F., Liang, X., Gong, X.-H., Chen, Y., Wang, F., Zheng, H., Wu, Z., Miao, N., Hadler, S. C., Hutin, Y. J., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.07.048 · Cited by 48
Sun, K., Zheng, R., Lei, L., Zhang, S., Zeng, H., Wang, S., Li, L., Chen, R., Han, B., Peng, J., et al. (2022) · China CDC Weekly · doi:10.46234/ccdcw2022.216 · Cited by 23
Self-citation
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Qin, J., Xue, L., Hao, A., Guo, X., Jiang, T., Ni, Y., Liu, S., Chen, Y., Jiang, H., Zhang, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03064-w · Cited by 254
Self-citationZhu, W., He, B., Wang, X., Du, Y., Young, K., & Jiang, S. (2025) · BMC Public Health · doi:10.1186/s12889-025-23475-9 · Cited by 74
Ge, R.-T., Xiong, F., Chen, Z.-B., Wang, Y., Zheng, L., Zhou, J., Wu, D., & Zhang, S.-Y. (2025) · Chem · doi:10.1016/j.chempr.2025.102489 · Cited by 28
Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3691 · Cited by 17
Metadata
- Authors
- Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J.
- Venue
- Journal of the National Cancer Center
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 4
- Issue
- 1
- Pages
- 47-53
- ISSN
- 2096-8663 (ISSN-L)
- 2667-0054
- OpenAlex
- W4391671392
- Cited by
- 2,243
- References
- 17
- FWCI
- 343.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.